Duloxetine Capsule, Delayed Release
Product Images NDC 68788-7935

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68788-7935). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Duloxetine Delayed Release Cap Usp 30mg

Duloxetine Delayed-Release Capsule USP 30 mg packaging label. The label states it is generic for Cymbalta, contains 33.7 mg Duloxetine Hydrochloride equivalent to 30 mg Duloxetine, and is manufactured by Ajanta Pharma USA Inc. The label includes placeholders for package size, expiration date, lot number, batch number, and instructions. Also present is a yellow box with bilingual directions to take capsules every specified hours, and a caution warning against transfer of the drug to others. Barcode and Preferred Pharmaceuticals, Inc. logo included.*

FDA Label Image

Figure1 (Duloxetine Fig1)

A line graph comparing the proportion of patients with relapse over time (days) from randomization between Duloxetine treatment and placebo. The x-axis shows time in days up to about 200, and the y-axis shows the proportion of patients with relapse from 0.0 to 1.0. The graph indicates a lower relapse proportion for patients treated with Duloxetine compared to placebo throughout the study period.*

FDA Label Image

Figure10 (Duloxetine Fig10)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline (BOCF). It shows two groups: placebo and duloxetine 60/120 mg once daily. The duloxetine group exhibits higher patient improvement percentages across increasing pain improvement thresholds compared to placebo.*

FDA Label Image

Figure2 (Duloxetine Fig2)

Kaplan-Meier curve showing the proportion of patients with relapse over time from randomization in days, comparing placebo (dashed line) and duloxetine treatment (solid line). The graph illustrates relapse rates over a period of up to 250 days.*

FDA Label Image

Figure3 (Duloxetine Fig3)

A line graph depicting the percentage of patients improved at various levels of percent improvement in pain from baseline for different treatments: Duloxetine 60 mg BID, Duloxetine 60 mg QD, Duloxetine 20 mg QD, and Placebo. The x-axis represents percent improvement in pain from baseline, while the y-axis shows the percentage of patients improved.*

FDA Label Image

Figure4 (Duloxetine Fig4)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, and Placebo, with both Duloxetine groups showing higher patient improvement than the placebo across the pain improvement range.*

FDA Label Image

Figure5 (Duloxetine Fig5)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine 60 mg taken twice daily, Duloxetine 60 mg taken once daily, and placebo groups. The vertical axis shows percentage of patients improved, and the horizontal axis shows percent improvement in pain from baseline, with data points spanning from >0% to 100% improvement.*

FDA Label Image

Figure6 (Duloxetine Fig6)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. The graph compares Duloxetine at 120 mg, 60 mg, and 20 mg once daily doses to placebo, with data points plotted for varying levels of pain improvement from more than 0% to 100%.*

FDA Label Image

Figure8 (Duloxetine Fig8)

Line graph comparing the percentage of patients improved against percent improvement in pain from baseline, showing results for placebo and Duloxetine 60/120 mg once daily. The graph plots two descending lines illustrating higher patient improvement percentages for Duloxetine across various pain improvement thresholds.*

FDA Label Image

Figure9 (Duloxetine Fig9)

A line graph comparing the percentage of patients improved versus percent improvement in pain from baseline, showing two curves for Placebo and Duloxetine 60 mg once daily. The x-axis represents percent pain improvement from 0 to 100, and the y-axis shows the percentage of patients improved from 0% to 100%. Duloxetine shows higher patient improvement percentages at various pain improvement levels than Placebo.*

FDA Label Image

Structure (Duloxetine Structure)

Chemical structure of duloxetine hydrochloride, showing the arrangement of fused rings including a naphthalene group and a thiophene ring, along with its methylaminoethyl side chain and associated hydrochloride component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.